Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Seasonal recombinant trivalent VLP influenza vaccine - Aramis Biotechnologies

Next Previous
Drug Profile

Seasonal recombinant trivalent VLP influenza vaccine - Aramis Biotechnologies

Alternative Names: Plant-based seasonal recombinant trivalent VLP influenza vaccine - Aramis Biotechnologies; TVLP vaccine - Aramis Biotechnologies

Latest Information Update: 01 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aramis Biotechnologies
  • Class Influenza virus vaccines; Plant proteins; Synthetic vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Influenza virus infections

Most Recent Events

  • 18 Dec 2025 Preclinical trials in Influenza virus infections (Prevention) in Canada (Parenteral) prior to December 2025
  • 18 Dec 2025 Aramis Biotechnologies plans a phase-I/II trial for Influenza virus infections (Prevention) in February 2026 (Parenteral, Injection), (NCT07291635)
  • 04 Dec 2024 Aramis Biotechnologies plans a phase-I/II trial for Influenza virus infections (Prevention) in Canada (Parenteral),

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top